FDA accepts Allergan’s Vraylar for review
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Read More
Tag: cariprazine
Allergan to file cariprazine for major depressive episodes
A late-stage study assessing Allergan/Gedeon Richter’s cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder has hit its primary target.
Read More
EU nod for Gedeon’s novel antipsychotic Reagila
European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
